AC Immune SA current report, Q4 FY2020

AC Immune SA Form 6-K Summary

Business Context and Reporting Period

This Form 6-K filing by AC Immune SA covers the month of November 2020. The report discloses the results of an Extraordinary General Meeting held on November 20, 2020.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters.

Material Changes

The primary material change reported is the approval of a new Board of Director member. No financial changes or operational shifts are detailed in this document.

Guidance, Outlook, and Risks

The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The content is limited to the voting results of the shareholder meeting.

Key Facts for Investors

  • Shareholders approved the election of Carl June as a new member of the Board of Directors.
  • The term for the new director extends until the end of the next ordinary General Meeting.
  • The filing includes a press release dated November 20, 2020, as Exhibit 99.1.
  • No financial performance data is included in this specific filing.